Novo Nordisk expects lack of Wegovy doses to continue until H2 2022

Issues at a sub-contractor have meant that Novo Nordisk only has a limited supply of obesity drug Wegovy in its lowest doses available until the second half of 2022. (Corrected)
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde
by marketwire, translated by daniel pedersen

(Corrected at 9:40 to clarify the extent of the supply issues)

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading